Abstract
A sample of 114 primary breast tumors and corresponding constitutional DNA were tested for loss of heterozygosity (LOH) of the YNZ22 and p53 genes, both located in the 17p13 region. Loss of the p53 allele was found in 28 of 44 primary breast carcinomas (64%). In contrast LOH in only 26 of 61 tumors (43%) was detected with the variable number of tandem repeats (VNTR) probe YNZ22 mapping at 17p13.3 close to the p53 locus at 17p13.1. Among 19 tumors informative for both probes allele loss at 17p13.3 never occurred without p53 involvement. These data suggest, that p53 is the target of 17p13 allelic deletions in human breast cancer. Immunohistochemistry showed overexpression of the p53 protein in 25 of 50 cases (50%) presumably reflecting activating point mutations. Overexpression was not correlated with allele loss but seemed to be closely related to the presence of point mutations in this study. No homozygous deletions or rearrangements of the p53 gene were detected. This would argue for an important role of heterozygous p53 mutations in human breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B (1989) Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 244:217–221
Banks L, Matlashewski G, Crawford L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529–534
Bartek J, Iggo R, Gannon J, Lane DP (1990a) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899
Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP (1990b) Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839–844
Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D (1990) Hu-man p53 is phosphorylated by p60-cdc2 and cyclinB-cdc2. Proc Natl Acad Sci USA 87:4766–4770
Bodner SM, Minna JD, Gazdar A, Jensen SM, DeAmico D, Carbone D, Mitsudomi T, Buchhagen D, Linoilla RI (1991) P53 mutations imperfectly correlate with immunostaining of lung cancers. Proc Am Assoc Cancer Res 32:307 (Abstract 1827)
Bodner SM, Minna JD, Jensen SM, DeAmico D, Carbone D, Mitsu-domi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar A, Linoilla RI (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 mutation. Oncogene 7:743–749
Buchman VL, Chumakov PN, Ninkina NN, Samarina OP, Georgiev GP (1988) A variation in the structure of the protein-coding region of the human p53 gene. Gene 70:245–252
Catoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988) P53 expression in breast cancer. Int J Cancer 41:178–183
Chen PL, Chen Y, Bookstein R, Lee WH (1990) Genetic mechanism of tumor suppression by the human p53 gene. Science 250:1576–1580
Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W III, Goldman ES, Moore D II, Balazs M, Liu E, Mayall BH, Smith HS (1991) Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 88:3847–3851
Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Granston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, Hoyheim B, Steel CM (1990) Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336:761–763
Davidoff AM, Humphery PA, Iglehart DJ, Marks JR (1991) Genetic basis for P53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88:5006–5010
de la Calle O, Yagüe J, Gaya A, Romero M, Vives J (1990) Biallelic Bgl II DNA polymorphism of the human p53 oncogene. Nucleic Acids Res 18:206
Devilee P, Cornelisse CJ, Kuipers-Dijkshoorn N, Jonker C, Pearson PL (1990) Loss of heterozygosity in human breast carcinomas: defining the smallest common region of deletion. Cytogenet Cell Genet 53:52–54
Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602
Lande DP, Benchimol S (1990) p53: oncogene or antioncogene? Genes Dev 4:1–8
Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456
Mackay J, Steel CM, Elder PA, Forrest APM, Evans HJ (1988) Allele loss on short arm of chromosome 17 in breast cancers. Lancet ii:1384–1385
Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E, Boiocchi M (1992) High frequency of p53 gene alterations association with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7:1159–1166
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kas-sel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Masharani U, Wolf D, Frossard PM (1988) Ban II and Sca I RFLPs at the human p53 gene locus. Nucleic Acids Res 16:7757
Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M, Martin C, Fujimoto E, Hoff M, Kumlin E, White R (1987) Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 235:1616–1622
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708
Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics 5:874–879
Prosser J, Thompson AT, Cranston G, Evans HJ (1990) Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5:1573–1579
Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555–7559
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Singh S, Meybohm I, Hartig C, Dege U, Jantke I, Simon M, Friedrichs K, Jonat W, Maass H, Goedde HW (1991) A molecular cytogenetic study of human breast cancer: Investigation of allele losses and rearrangements in defined regions of chromosomes 1, 11, 13 and 17 with specific RFLP and VNTR probes. In: Issinger OG, Henke nJ, KömpfJ, Driesel AJ (eds) Molecular biology in tumour research. 6th Annual Meeting 1990 Arbeitsgemeinschaft für Gen-Diagnostik e.V. Hüthig, Heidelberg. BTF5, Advances in Mol Genet 3:137–146
Singh S, Meybohm I, Patzak A, Simon M, Brunner E, Jantke I, Fried-richs K, Jonat W, Maass H, Goedde HW (1992) A molecular genetic investigation of c-erbB-2 amplification and expression in human primary breast cancer and allele losses at chromosome 17. In: Jonat W, Löning T (eds) International Symposium: Clinical and Scientific Aspects of Her2/Neu/ErbB-2. Springer, Heidelberg New York Toronto
Toguchida J, Ishizaki K, Nakamura Y, Sasaki MS, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, Yamamuro T (1989) Assignment of common allele loss in osteosarcoma to the subregion 17p13. Cancer Res 49:6247–6251
Varley JM, Brammar WJ, Lane PL, Swallow JE, Dolan C, Walker RA (1991) Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413–421
Vogelstein B (1990) A deadly inheritance. Nature 348:681–682
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Singh, S., Simon, M., Meybohm, I. et al. Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet 90, 635–640 (1993). https://doi.org/10.1007/BF00202481
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00202481